Executive Summary
The 12 filings reveal a surge in SPAC lifecycle events (7/12 filings), including IPOs raising $572M+ in trust proceeds (APEX $112M, Illumination $230M), non-redemption agreements to extend deadlines (Crown PropTech to March 2027), and promissory notes for operations (Artius II up to $1M), signaling robust M&A pipeline activity amid tight timelines. Completed M&A/divestitures dominate the rest (4/12), with accretive buys like Chatham Lodging's $92M hotel acquisition (RevPAR $116 vs prior sold $101, margins 42% vs 27%, +12% EBITDA) and Kratos' $353M Orbit deal, plus Albemarle's $670M asset sales for debt reduction; High Wire's $150k settlement clears $804k liabilities to enable takeover. Governance crises in Drugs Made In America entities (3 filings) highlight sponsor irregularities ($1.1M improper withdrawals post-IPO, no trust impact but CEO removals), contrasting positive sentiment (9/12 positive/neutral). No broad YoY/QoQ revenue trends due to transactional nature, but capital allocation leans toward accretive M&A/debt paydown vs dividends (Chatham +11% to $0.10/share). Portfolio-level: SPACs preserve ~$1B+ in trusts for deals; M&A valuations attractive ($156k/room Chatham, $13.73/share Orbit). Implications: Heightened M&A catalysts Q1-Q2 2026, watch SPAC redemptions and Drugs resolutions for volatility.
Tracking the trend? Catch up on the prior US Merger & Acquisition SEC Filings digest from March 05, 2026.
Investment Signals(10)
- HIGH WIRE NETWORKS↓(BULLISH)▲
Settled $804k disputed claims (incl. $336k payroll, $469k notes) for $150k (81% discount), clearing balance sheet liabilities as of Sep 30 2025 and enabling Thoth Aerospace takeover via share exchange; Porter resigns post-close
- APEX Tech Acquisition↓(BULLISH)▲
IPO raised $112M gross/$112M net to trust at $10/unit (11.2M units), plus $2.1M sponsor private placement; balance sheet solidifies de-SPAC hunt
- Crown PropTech Acquisitions↓(BULLISH)▲
Non-Redemption Agreements assign sponsor shares (1:40 ratio, monthly accrual from Apr 2026) to preserve trust funds ahead of Mar 9 EGM extension to Mar 2027
- Chatham Lodging Trust↓(BULLISH)▲
$92M acquisition of 589-room Hilton hotels at $156k/room (10% cap rate, +$10M EBITDA or 12% growth, +$0.10 adj FFO/yr) outperforms sold hotels (RevPAR $116 vs $101, margins 42% vs 27%); dividend +11% to $0.10/share
- KRATOS DEFENSE↓(BULLISH)▲
Completed $353M cash acquisition of Orbit Tech (100% shares at $13.73/share), delisting from Tel Aviv; funded from balance sheet, expands defense portfolio
- ALBEMARLE CORP↓(BULLISH)▲
$670M pre-tax proceeds from Ketjen stake sale (Mar 2026) + Eurecat JV (Jan 2026) for debt reduction; retains PCS business, enhances flexibility
- Illumination Acquisition Corp. I↓(BULLISH)▲
IPO $230M gross to trust (23M units at $10, incl. full over-allotment), +$6.25M private placement; no founder share forfeiture
- Artius II Acquisition↓(BULLISH)▲
$1M interest-free promissory note from sponsor (convertible at 10% premium to $11/share equiv.), no draws yet; supports operations to business combination
- Drugs Made In America (Both)(NEUTRAL-BULLISH)▲
Trust accounts intact ($507.8M II, $241.3M I as of Mar 6), no financial impacts from sponsor irregularities; leadership transition to Roger Bendelac (30+ yrs IB exp)
- Crown PropTech↓(BULLISH)▲
Proxy filed Feb 27 for Mar 9 EGM; non-redemptions expected to maintain trust post-vote vs baseline
Risk Flags(8)
Sponsor improper $1.1M withdrawals post-IPO (Sep 26-Dec 31 2025, incl. $566k overpayment not returned); CEO Lynn Stockwell removed Feb 28
Affiliate sponsor irregularities ($1.1M+$200k unrelated expenses) led to CEO Stockwell removal Feb 28; board demands unmet Feb 12
- Drugs Made In America II / Sponsor Accountability[MEDIUM RISK]▼
Overpayments through Dec 31 2025 unreturned despite Feb 12 board directive; new CEO Bendelac comp TBD
- High Wire Networks / Payment Timing↓[MEDIUM RISK]▼
Porter settlement payments from 5% future ELOC proceeds, no fixed deadline; delays possible
- Crown PropTech / Extension Uncertainty↓[MEDIUM RISK]▼
Non-Redemption Agreements 'not expected to increase approval likelihood' for Mar 9 EGM; no incentive assurances
- Artius II Acquisition / Liquidity↓[LOW-MEDIUM RISK]▼
Up to $1M sponsor note needed for operations; convertible on default but no draws signal cash burn
- Chatham Lodging / Leverage↓[LOW RISK]▼
Hotel acquisition raises net debt/EBITDA +50 bps via credit facility borrowings
- Illumination Acquisition / Costs↓[LOW RISK]▼
$13.3M transaction costs (incl. $8M deferred UW fees) create $7.1M shareholders' deficit post-$231M assets
Opportunities(8)
- HIGH WIRE NETWORKS / Takeover Closing↓(OPPORTUNITY)◆
Liability clearance ($804k to $150k) paves way for Thoth control via Securities Exchange Agreement; monitor ELOC-funded payments
- Chatham Lodging / Portfolio Optimization↓(OPPORTUNITY)◆
Accretive swap (new hotels +15% RevPAR, +550 bps margins vs sold); +11% dividend, record Mar 31/pay Apr 15
- KRATOS DEFENSE / Synergies↓(OPPORTUNITY)◆
$353M Orbit buy (defense tech) at potentially undervalued $13.73/share; post-merger integration catalysts
- ALBEMARLE CORP / Capital Return↓(OPPORTUNITY)◆
$670M proceeds bolster debt reduction vs peers; refocus on core catalysts, trading discount possible
- Crown PropTech / Extension Success↓(OPPORTUNITY)◆
Mar 9 EGM could extend to 2027, preserving trust via non-redemptions (1:40 share transfer)
- APEX Tech / De-SPAC Hunt↓(OPPORTUNITY)◆
$112M trust + sponsor commitment positions for tech M&A; NYSE listing
- Illumination Acquisition / Scale↓(OPPORTUNITY)◆
Largest IPO here at $230M trust; full over-allotment avoids founder dilution
- Drugs Made In America Entities / Stabilization(OPPORTUNITY)◆
Trusts secure ($749M combined), new CEO with IB expertise; pharma M&A target rich
Sector Themes(5)
- SPAC Extension & Preservation Tactics◆
7/12 filings SPAC-related; non-redemptions (Crown 1:40 shares) and $1B+ trusts (e.g., Illum $230M, APEX $112M) counter redemption risks, extending timelines to 2027 [Bullish for M&A liquidity]
- Accretive M&A Valuations◆
Deals at discounts/attractiveness (High Wire 81% claim haircut, Chatham $156k/room 10% cap/42% margins, Kratos $13.73/share); outperforms internals (Chatham +15% RevPAR) [M&A momentum signal]
- Governance Fixes in Pharma SPACs◆
4/12 Drugs filings flag sponsor irregularities ($1.1M+ withdrawals, no trust hit) but CEO swaps to experienced leadership; 2 trusts >$240M each intact [Watch for de-SPAC acceleration]
- Capital Recycling for Flexibility◆
Divestures (Albemarle $670M) and settlements fund debt paydown/deals; Chatham +11% dividend amid lodging portfolio upgrade [Shareholder-friendly shifts]
- Blank Check IPO Surge◆
3 IPOs Mar 2026 (APEX, Illumination, ref Artius) raised $572M+ to trusts at $10/unit; private placements add sponsor skin [Early-stage M&A funding boom]
Watch List(7)
Mar 9 2026 Extraordinary General Meeting on deadline extension to Mar 11 2027; monitor redemption levels and trust preservation [Mar 9]
Record date Mar 31, payable Apr 15 2026 at $0.10/share (+11%); track leverage post-debt draw [Mar 31/Apr 15]
Thoth Aerospace share exchange post-settlement; watch Porter resignation and ELOC put orders for payments [Imminent Q1 2026]
- Drugs Made In America II / Sponsor Resolution👁
Follow-up on $1.1M irregularities and Bendelac leadership; trust $507.8M as of Mar 6 [Ongoing Q2]
- Drugs Made In America I / Trust Integrity👁
$241.3M trust confirmed intact; monitor affiliate spillover and de-SPAC progress [Ongoing]
$1M sponsor note activation for operations; conversion triggers on business combo/liquidation [Q2 2026]
Post-Mar 2 merger financial impacts/metrics disclosure; options cashed out [Q2 earnings]
Filing Analyses(12)
06-03-2026
High Wire Networks, Inc. entered into a Global Settlement and Mutual Release Agreement effective March 3, 2026, with Thoth Aerospace Inc., Dennis O'Leary, and Mark W. Porter, settling Porter's disputed claims of approximately $804,345 (including $265,000 principal, $203,964 interest, and $335,382 unpaid compensation) for a total of $150,000, resulting in cancellation of all related promissory notes. This settlement clears prior related-party liabilities recorded as $335,382 accrued payroll and $468,964 notes payable as of September 30, 2025, and facilitates closing of a Securities Exchange Agreement under which Thoth will acquire control of the Company via share exchange. Porter will resign as CEO and director upon closing, with payments to be made from 5% of proceeds from future ELOC put orders.
- ·December 2023 Note originally $165,000; amended June 28, 2024; 2021 Note amended June 28, 2024
- ·Payments to Porter: within 5 business days of each ELOC Put Order receipt, no fixed deadline for full payment
- ·All Notes deemed cancelled upon Agreement execution; Porter to deliver marked originals
- ·Company to recognize gain/loss on debt extinguishment per GAAP in SEC filings
06-03-2026
APEX Tech Acquisition Inc. consummated its initial public offering (IPO) on February 27, 2026, selling 11,197,131 public units at $10.00 each, generating gross proceeds of $111.97M. Simultaneously, the company closed a private placement of 208,971 units to its sponsor, APEX INNOVATION ACQUISITION CORP., for $2.09M in proceeds. A total of $111.97M in net proceeds from both transactions was deposited into a trust account for the benefit of public shareholders.
- ·Audited balance sheet as of February 27, 2026 included as Exhibit 99.1
- ·Securities traded on The New York Stock Exchange
- ·Company address: 13501 Katy Fwy, Houston, TX 77079
06-03-2026
On March 5, 2026, Crown PropTech Acquisitions and its co-sponsor CIIG Management III LLC entered into Non-Redemption Agreements with certain investors ahead of the March 9, 2026 Extraordinary General Meeting to vote on extending the initial business combination deadline from March 11, 2026 to March 11, 2027. The agreements involve the sponsor assigning one Class B ordinary share for each 40 public shares not redeemed, accruing monthly from April 11, 2026 until business combination completion, in exchange for investors agreeing not to redeem shares. While not expected to increase approval likelihood, this is anticipated to preserve more funds in the trust account post-meeting, with no assurances provided on incentives.
- ·Record date for Extraordinary General Meeting: February 13, 2026
- ·Proxy Statement filed with SEC: February 27, 2026
- ·Non-Redemption Agreements to be disclosed via Form 8-K with aggregate Investor Shares
06-03-2026
On February 28, 2026, Lynn Stockwell was removed as Chief Executive Officer, Executive Chair, and Board member due to the Sponsor's improper withdrawals totaling $1.1M from working capital post-IPO, including a $566k overpayment that was not returned despite Board demands. Roger Bendelac was appointed as the new CEO effective the same date, with compensation to be determined later. The incident highlights governance issues but ensures leadership continuity.
- ·Sponsor withdrawals occurred between IPO completion on September 26, 2025, and September 30, 2025 ($1.1M), with additional overpayment adjustments through December 31, 2025.
- ·Board directed Sponsor to return full overpayment on February 12, 2026; Stockwell agreed to resign on February 18, 2026.
- ·Roger Bendelac, 69, has over 30 years in investment banking; no family relationships or related party transactions with the Company.
06-03-2026
On February 28, 2026, Lynn Stockwell was removed as Chief Executive Officer, Executive Chair of the Board, and Board member of Drugs Made In America Acquisition Corp. following issues with the sponsor of its affiliate, Drugs Made In America Acquisition II Corp., which improperly withdrew $1.1M from the affiliate's working capital account between September 26 and September 30, 2025, including a $566,269 overpayment and at least $200,000 more for unrelated expenses. Roger Bendelac was appointed as the new CEO effective the same date, with compensation to be determined later. The resignations stem from the sponsor's inability to repay overpayments as directed on February 12, 2026.
- ·Sponsor withdrawals from affiliate occurred between completion of affiliate's IPO on September 26, 2025, and September 30, 2025; additional withdrawals between September 30, 2025, and December 31, 2025.
- ·Affiliate Board directed sponsor to return full overpayment on February 12, 2026; learned on same date sponsor unable to repay.
- ·Stockwell agreed to resign on February 18, 2026, at request of both Company and Affiliate Boards; resignation effective February 28, 2026 upon receipt.
06-03-2026
Chatham Lodging Trust completed the acquisition of six Hilton-branded hotels (589 rooms) for $92 million ($156,000 per room), featuring younger properties (average age 10 years) with higher RevPAR ($116 vs. $101 for sold hotels) and EBITDA margins (42% vs. 27%), following sales of six older hotels for ~$100 million over the past 18 months. The company increased its quarterly common dividend by 11% to $0.10 per share, payable April 15, 2026. This accretive deal (10% cap rate, adds ~$10M Hotel EBITDA or 12% increase, +$0.10 adjusted FFO/year) raises net debt to EBITDA ratio by 50 basis points.
- ·Acquired hotels located in Joplin, Mo. (two), Effingham, Ill. (two), Paducah, Ky. (two).
- ·Dividends payable April 15, 2026 to shareholders of record March 31, 2026.
- ·Acquisition funded with available cash and revolving credit facility borrowings.
- ·Acquired portfolio included in Chatham results for only 10 months in 2026.
06-03-2026
Kratos Defense & Security Solutions, Inc. completed its acquisition of Orbit Technologies Ltd. on March 2, 2026, via a merger, acquiring 100% of Orbit's ordinary shares for approximately $352.7 million in cash funded from its balance sheet, at $13.725 per share. Orbit, previously publicly traded on the Tel Aviv Stock Exchange, is now an indirect wholly owned subsidiary of Kratos. No financial impacts or performance metrics were disclosed in this filing.
- ·Merger Agreement dated November 4, 2025, previously disclosed in 8-K filed November 7, 2025
- ·Orbit ordinary shares delisted from Tel Aviv Stock Exchange post-merger
- ·All outstanding Orbit options fully vested and canceled for cash payment based on Merger Consideration
06-03-2026
Albemarle Corporation completed the sale of a controlling stake in Ketjen Corporation’s refining catalyst solutions business to KPS Capital Partners on March 2, 2026, retaining a minority stake and 100% ownership of Ketjen’s Performance Catalyst Solutions business. Combined with the January 2026 sale of its 50% interest in the Eurecat joint venture to Axens SA, Albemarle received $670M in pre-tax proceeds for debt reduction and general corporate purposes. The transaction strengthens portfolio focus and financial flexibility, with no declines or flat metrics reported.
- ·Goldman Sachs & Co. LLC acted as exclusive financial advisor and K&L Gates LLP as legal advisor to Albemarle.
- ·KPS has majority Board control and operational control of Ketjen.
06-03-2026
Illumination Acquisition Corp. I, a blank check company, consummated its IPO on March 2, 2026, selling 23,000,000 units (including 3,000,000 from over-allotment) at $10.00 per unit for gross proceeds of $230M, plus a simultaneous private placement of 625,000 units for $6.25M. Proceeds funded a $230M trust account at $10.00 per public share. The balance sheet as of March 2 reflects total assets of $231.1M but a shareholders' deficit of $7.1M primarily due to $13.3M in transaction costs including $8.05M deferred underwriting fees.
- ·Underwriting over-allotment option exercised in full on February 27, 2026, eliminating forfeiture of 1,000,000 Class B founder shares.
- ·Sponsor purchased 395,000 Private Placement Units; BTIG, LLC purchased 230,000.
- ·Each warrant exercisable for one Class A ordinary share at $11.50.
- ·Company incorporated November 18, 2025; registration statement effective February 26, 2026.
06-03-2026
Artius II Acquisition Inc., a Cayman Islands blank check company (SPAC), entered into a promissory note dated March 6, 2026, with Artius II Acquisition Partners LLC for principal advances of up to $1,000,000 to fund ongoing operations, interest-free, with a minimum drawdown of $10,000. The note matures upon closing of the initial business combination or company liquidation and is convertible at the payee's election into Private Placement Shares at a 10% premium ($11/share equivalent) upon business combination, liquidation, or default. No amounts have been drawn down as of the filing.
- ·Note governed by New York law; no personal liability for officers/directors/shareholders.
- ·Payee waives claims against the SPAC's IPO trust account.
- ·References Private Placement Units Purchase Agreement dated February 12, 2025.
06-03-2026
Drugs Made In America Acquisition II Corp. disclosed that its sponsor made improper withdrawals (Irregularities) from the working capital account between the IPO on September 26, 2025, and December 31, 2025. The board confirmed these did not affect the Trust Account, which holds approximately $507.8M as of March 6, 2026. No other financial impacts or period-over-period metrics were reported.
- ·Irregularities occurred between September 26, 2025 (IPO completion) and December 31, 2025
- ·Securities: Units (DMIIU), Ordinary Shares (DMII), Rights (DMIIR) listed on Nasdaq
06-03-2026
Drugs Made In America Acquisition Corp. confirmed that irregularities, consisting of improper withdrawals by the sponsor from its affiliate Drugs Made In America Acquisition II Corp.'s working capital account between September 26, 2025, and December 31, 2025, did not impact the Company's Trust Account. As of March 6, 2026, the Trust Account balance stands at approximately $241.3M, providing reassurance to investors. No losses or declines were reported for the Company's funds.
- ·Irregularities occurred between completion of affiliate's IPO on September 26, 2025, and December 31, 2025.
- ·Company's securities trade on Nasdaq Stock Market LLC.
Get daily alerts with 10 investment signals, 8 risk alerts, 8 opportunities and full AI analysis of all 12 filings
🇺🇸 More from United States
View all →March 26, 2026
US Pre-Market SEC Filings Roundup — March 26, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 25, 2026
Biotech Small-Cap Approvals — March 25, 2026
Biotech Small-Cap Approvals
March 25, 2026
New Drug Approvals (Original) — March 25, 2026
New Drug Approvals (Original)